| Document |
Document Title |
|
WO/2024/076692A1 |
Disclosed are novel heterobifunctional compounds that induce p53Y220C acetylation, and methods for use of such compounds in the treatment of p53Y220C-mediated diseases.
|
|
WO/2024/073871A1 |
It provides compounds of Formula I, a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing. It also provides compositions comprising the compounds of Formula I...
|
|
WO/2024/012566A9 |
The present disclosure relates to an antibody, a payload and a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.
|
|
WO/2024/077137A1 |
Described herein are crystalline forms of 5-(4-((7-cyclopropyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl
)methyl)piperazin-1-yl)-N-methylpicolinamide (compound 1), or a pharmaceutically acceptable salt or solvate thereof.
|
|
WO/2024/076891A1 |
Disclosed herein are compounds of Formula (IV), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (IV...
|
|
WO/2024/076300A1 |
Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...
|
|
WO/2024/074049A1 |
Provided are a pharmaceutical composition for thyroid undifferentiated cancer and use thereof in the preparation of a medicament for preventing and/or treating thyroid undifferentiated cancer. The pharmaceutical composition comprises jac...
|
|
WO/2024/074724A1 |
The present invention relates to binding protein or antibody comprising one antigen binding domain that binds to CD47, said antigen binding domain comprising a heavy chain variable region that comprises three complementarity determining ...
|
|
WO/2024/076672A1 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/077277A1 |
Disclosed herein are antibody drug conjugates (ADCs), drug-linkers for ADCs, and tunable phosphate-based linkers. ADCs of the present disclosure include antibodies such as anti-CD70 antibodies conjugated to duocarmycin analogs via phosph...
|
|
WO/2024/074498A1 |
The present invention relates a therapeutic combination of a BTN3A activating antibody, a Bcl-2 family inhibitor and hypomethylating agents that is particularly useful for the treatment of cancer, in particular hematological malignancies...
|
|
WO/2024/074611A1 |
The present invention relates to compounds of formula (I) and salts, stereoisomers, atrop-isomers, rotamers, tautomers or N- oxides thereof that are useful as PRMT5 inhibitors. The present invention further relates to the compounds of fo...
|
|
WO/2024/076550A1 |
Disclosed is a method of using Netrin-1 (NTN1) driven rejuvenation of an aged hematopoietic system based on its shown dependency of reestablishing integrity of aged bone marrow niche and reactivating DNA damage response (DDR). NTN1 is sh...
|
|
WO/2024/075003A1 |
The invention provides a complex for use in various therapeutic applications, and methods of treatment using the complex, or pharmaceutical compositions comprising the complex. The complex is particularly useful for treating malignant tr...
|
|
WO/2024/076663A1 |
Provided herein is (R)-7-chloro-2-((lr,4R)-4-(3-methoxyazetidin-1-yl)cyclohexyl
)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydro
pyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt th...
|
|
WO/2024/077140A1 |
In the various aspects and embodiments, the present disclosure provides cell populations or cell "banks" thereof (e.g., cell collections) to provide immune compatible, allogeneic cell therapies covering global, ethnic, and disease-specif...
|
|
WO/2024/074977A1 |
This disclosure relates to compounds of Formula (I) (I), or a pharmaceutically acceptable salt thereof, in which R3, R4, L2, W, X, Y, and Z are as 5 defined herein, to pharmaceutical compositions comprising such compounds and salts; to p...
|
|
WO/2024/077057A1 |
Compounds having activity as kinase inhibitors are provided. The compounds have Structure (I), or a stereoisomer, tautomer, or salt thereof, wherein, R1, R3, and m are as defined herein. Methods associated with preparation and use of suc...
|
|
WO/2024/074102A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-6, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/073845A1 |
The present application relates to methods for expanding hematopoietic stem cells (HSC) and/or hematopoietic progenitor cells (HPC) ex vivo and/or in vivo. The methods comprise culturing the HSCs and/or HPCs in the presence of a selectiv...
|
|
WO/2024/077174A1 |
The present disclosure provides methods of preparing immune cells, e.g., T cells and/or NK cells, comprising contacting the cells with programmable cell-signaling scaffolds in a medium comprising at least about 5 mM potassium ion and edi...
|
|
WO/2024/074604A1 |
The present invention relates to compound of general formula (I): wherein the variables take the various meanings, pharmaceutical compositions containing them and their use in medicine, particularly in cancer such as Glioblastoma. The co...
|
|
WO/2024/077006A1 |
Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
|
|
WO/2024/074107A1 |
The present invention belongs to the field of biopharmaceuticals. Provided are a keratin YK93-2, a nucleic acid molecule encoding the same, an expression vector comprising the nucleic acid molecule, a host cell comprising the expression ...
|
|
WO/2024/074111A1 |
The present invention pertains to the field of biopharmaceuticals and provides a keratin YK93-9, a nucleic acid molecule encoding same, an expression vector comprising the nucleic acid molecule, a host cell that contains the expression v...
|
|
WO/2024/077270A1 |
Described herein are immunoresponsive cells engineered to express cytokines and chimeric receptors. Also described herein are nucleic acids, cells, and methods directed to the same.
|
|
WO/2024/076514A1 |
This application provides isolated antibodies (Abs), e.g., monoclonal antibodies (mAbs), that bind specifically to C-C Motif Chemokine Receptor 8 (CCR8), and bispecific antibodies targeting CCR8 and CTLA-4, and methods for treating a can...
|
|
WO/2024/076537A1 |
The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a s...
|
|
WO/2024/074110A1 |
The present invention relates to the field of biological pharmacy, provides keratin YK93-5, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or...
|
|
WO/2024/077130A1 |
The present disclosure relates to compositions and methods for treating bladder cancer. In some embodiments the compositions and methods involve using antisense (AS) nucleic acids directed against Insulin-like Growth Factor 1 Receptor (I...
|
|
WO/2024/074553A1 |
The invention relates to novel membrane-permeable constructs and membrane-permeable constructs for use in the transport of cargo across a lipid membrane and subsequent delivery of said cargo into a cell. The cargo may be mRNA and the cel...
|
|
WO/2024/074959A1 |
This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of metastatic castration-resistant prostate cancer a...
|
|
WO/2024/075696A1 |
The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc. A compound represented by formula (1) or a pharma...
|
|
WO/2024/077158A1 |
In various aspects and embodiments, the present disclosure provides methods for generating T cell populations for cell therapy, including T lymphocytes (T cells) and progenitor T cells. In various embodiments, the invention provides for ...
|
|
WO/2024/076985A2 |
Methods of treating SMARCA4-deleted cancer cells using a selective SMARCA2 degrader and a KRAS targeting therapy in a combination therapy is described.
|
|
WO/2024/076657A1 |
3 β-hydroxy-5-cholestenoic acid 3-sulfate (CA3S), a sulfated derivative of 3β-hydroxy-5-cholestenoic acid (CA), is provided. Both CA and CA3S have potent cholesterol and triglyceride lowering and anti-inflammatory activities. Methods o...
|
|
WO/2024/077037A1 |
The present disclosure relates to compositions and methods for the detection of 3' UTR somatic mutations and/or variants for use as prognostic assay for response to cancer immunotherapy. The present disclosure allows for the use of one o...
|
|
WO/2024/073842A1 |
The present disclosure generally relates to binding agents that are capable of targeting tumor cells and immune cells. The binding agents of the present disclosure are multispecific and comprise antigen binding domains that are capable o...
|
|
WO/2024/074104A1 |
The present invention belongs to the field of biopharmaceuticals. Provided in the present invention are keratin YK93-8, a nucleic acid molecule encoding same, an expression vector containing the nucleic acid molecule, a host cell contain...
|
|
WO/2024/075067A1 |
The present invention relates to a compound selected from a polynucleotide coding for Glypican-1, a vector, and a host cell genetically engineered so as to express Glypican-1 The present invention further relates to the use of the compou...
|
|
WO/2024/076781A1 |
The present disclosure relates to polynucleotides and methods of inhibiting the activities of development- associated pathways, including the Wnt, Hedgehog, and Notch pathways, and the invasive capacity of malignant cells to treat primar...
|
|
WO/2024/075070A2 |
The present invention relates to a compound represented by chemical formula 1 as an SOS1 inhibitor, optical isomers thereof, stereoisomers thereof, solvates thereof, isotopic variants thereof, tautomers thereof, or pharmaceutically accep...
|
|
WO/2024/076674A1 |
The present disclosure provides compounds having activity as inhibitors of the G12C mutant KRAS protein, pharmaceutical compositions comprising the compounds, and methods of treating certain disorders, such as cancer, including but not l...
|
|
WO/2024/077244A1 |
The present disclose includes, among other things, compounds that treat or lessen the severity of cancer, pharmaceutical compositions and methods of making and using the same.
|
|
WO/2024/074127A1 |
Provided compounds of Formula (I), a tautomer thereof, a deuterated derivative of the compound or the tautomer, and a pharmaceutically acceptable salt of the foregoing, compositions comprising the compounds of Formula (I), a tautomer the...
|
|
WO/2024/077264A2 |
The present disclosure provides methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of a GPX4 inhibitor and a PARP inhibitor, wherein the subject is BRCA1 deficient (e.g., ...
|
|
WO/2024/077036A1 |
This disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, and compounds of Formula (II), and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (...
|
|
WO/2024/041544A9 |
Provided is a method of preparing an antibody with site-specific modification. Three of four interchain disulfide bonds within the antibody are selectively reduced firstly. By the site-specific modification of the antibody, many kinds of...
|
|
WO/2024/076155A1 |
The present invention evaluated a method for producing a novel ENL/AF9 YEATS domain inhibitor, wherein the ENL/AF9 YEATS domain inhibition ability of a compound made through the production method was evaluated, and the novel compound was...
|
|
WO/2024/077159A1 |
The present disclosure provides for efficient ex vivo processes for generating B cell lineages from human induced pluripotent stem cells (iPSCs). Cells generated according to the disclosure in various embodiments are functional and/or mo...
|
